AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
The following is a summary of "Macrotroponin interference and association with cardiotoxicity in patients receiving ...
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for ...
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of trastuzumab emtansine (Kadcyla), a targeted treatment specifically designed ...
Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, ...
Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results